Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 3 Warts 1 Uveal Melanoma 1 Tuberous Sclerosis 1 Seizures 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, T-Cell 1 Lennox Gastaut Syndrome 1 Hyperthermia 1 Hemorrhage 1 Hematologic Neoplasms 1 Glioblastoma 1 Epilepsies, Myoclonic 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Solutions × 1 year × Clear all

NCT03233152 2025-11-21

GlitIpNi

Universitair Ziekenhuis Brussel

Phase 1/2 Active not recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡